Zum Hauptinhalt springen
xMedica

NCT07570316ClinicalTrials.gov

A Study to Assess Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease

A Phase 3, Randomized, Double-Masked, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Efgartigimod PH20 SC PFS in Adult Participants With Graves' Disease Inadequately Controlled With Antithyroid Drugs

RekrutiertNimmt laut Registereintrag derzeit Teilnehmende auf.
Diese Studie kontaktieren

Kurz gefasst

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is…

Phase 3230 Teilnehmende gesucht35 Studienzentren3 Länder

Kategorien

In 1 Register registriert

Eine Studie kann in mehreren Registern registriert sein. Wir zeigen sie einmal und verlinken jeden Eintrag, den wir haben.

Die Studieninformationen werden so angezeigt, wie sie vom Register veröffentlicht wurden, in ihrer Originalsprache.

Interesse an dieser Studie?

Anmelden oder ein Konto erstellen um Ihr Interesse zu bekunden und diese Studie zu verfolgen.

How this study is set up

The points below are drawn from the public registry record for this study. Each one cites the field or sentence it came from. A dash (—) means the record does not state something — not that it is missing or wrong. Many well-run studies, especially small ones, leave some of these blank.

  • Present: Registered before enrolment beganFirst posted 2026-05-06; recorded start 2026-06-10
  • Present: Has a defined primary outcomeA primary outcome measure is listed in the record
  • Present: The primary outcome states a time frameThe primary outcome measure records a time frame
  • Present: Participants are randomly assignedAllocation is recorded as randomised
  • Present: Has a comparison groupThe record lists a placebo or comparator arm, or more than one study arm
  • Present: Uses blinding (masking)A masking level is recorded in the record
  • Not stated: An ethics committee is not stated in the registry recordThis registry's ingested record has no ethics-committee field
  • Not stated: Regulatory oversight (such as an IND or IDE) is not stated in the registry recordThis registry's ingested record has no regulatory-authorisation field
  • Not stated: A data monitoring committee is not stated in the registry recordThis registry's ingested record has no data-monitoring-committee fieldA data monitoring committee is not required for many smaller studies, and its absence here is not unusual.
  • Present: No cost to participants is mentioned in the recordChecked the summary, description and eligibility text; no cost-to-participant phrase found
  • Present: Sponsor has 87 other studies in this databaseCounted from the lead sponsor named in the record (argenx)
  • Present: Sponsor has posted results for at least one studyBased on the sponsor’s studies in this database
  • The record lists 2 conditions.
  • Lead sponsor type recorded as: industry.
  • Intervention regulatory context: investigational, within a phased regulatory pathway.

Trial stature

Three independent measures of this study, described from its registry record — not a recommendation about it. A rigorous study by investigators nobody has heard of is better evidence than a weak study led by a famous one. How these are scored.

Methodological rigourSTRONG

A strong methodological design for a phase 3 study, judged from its ClinicalTrials.gov record.

How this score is built
  • Randomised allocation20/20

    Participants are randomly allocated between arms

  • Blinding20/20

    Quadruple-blind

  • Control arm13/15

    Placebo / sham control arm

  • Primary-outcome specificity10/10

    Named primary outcome with a defined time frame

  • Endpoint type3/10

    Surrogate or intermediate endpoint (conservative default)

  • Multi-centre8/8

    Multi-centre: 18 sites

  • Data monitoring committee0/7

    Data monitoring committee not stated in the record

  • Prospective registration5/5

    Registered before the study start date

  • Protocol / SAP posted0/5

    No protocol or SAP posted to the registry

ScaleMEDIUM

A medium-sized study, international in scope: 230 participants (target), run at 35 sites, across 3 countries.

How this score is built
  • Enrolment23/40

    230 participants (target)

  • Site count15/25

    18 sites

  • Country count7/15

    2 countries

  • Planned duration9/10

    Planned over about 47 months

  • Sponsor scale7/10

    argenx has led 83 trials in our corpus

Investigator standingUNKNOWN

We have no verifiable track record for the investigator named on this trial. That is common for early-career investigators and for records held outside ClinicalTrials.gov — it is not a negative signal.

How this score is built
  • Investigator standing0/100

    No investigator recorded in the registry for this trial

These describe the registry record only, and today we hold ClinicalTrials.gov data. Absent fields lower a score, and absence often reflects registration practice rather than study quality. A high-stature trial is not necessarily safer or a better choice for you — enrolling in a large definitive trial can mean a higher chance of receiving placebo, while a small early-phase study may be the only route to a new therapy.

Zusammenfassung

The main purpose of this study is to look at how efgartigimod affects thyroid function in adults with Graves' Disease (GD). The study will also check whether efgartigimod is safe and well tolerated. It will look at how efgartigimod is distributed and eliminated in the body, how it changes antibody levels, and how the immune system responds to it. The study consists of a part A double-blinded treatment period, a part B treatment/observation period and a part C open-label treatment/observation period. During the part A and part B treatment periods, participants will receive efgartigimod PH20 SC via Prefilled Syringe (PFS) or placebo. During the part C open-label treatment period, participants will receive efgartigimod PH20 SC PFS. Participation in the different parts of the study will depend on the participant's response to treatment. The total study duration for participants ranges from 63 to 135 weeks, depending on the response to treatment. More information can be found here: https://clinicaltrials.argenx.com/vitalithy

Erkrankungen

  • Graves' Disease
  • Graves Disease

Eignung

Eignung
GeschlechtAlle
Alter18 Years – Kein Höchstalter
Gesunde FreiwilligeNein

Eignung im Wortlaut des Registers

Inclusion Criteria: * Is at least 18 years of age and the local legal age of consent for clinical studies when signing the ICF. * Has a documented diagnosis of GD with TRAb (anti-thyrotropin receptor antibody) levels \>=ULN (upper limit of normal) at screening. * Has active hyperthyroidism due to GD with TSH (thyroid-stimulating hormone) \<0.1 mIU/L at screening. * Has been treated with MMI (methimazole) or CBZ (carbimazole) for at least 3 months before screening. Exclusion Criteria: * History of hyperthyroidism not caused by GD (eg, toxic adenoma or toxic multinodular goiter). * History of RAI (radioactive iodine) therapy or received a total thyroidectomy. * T3- or T4-containing medication or supplement (eg, levothyroxine, liothyronine, desiccated thyroid preparations, or thyroid-support supplements) received \<6 weeks before screening. * Any complication of hyperthyroidism or underlying medical condition that would put the participant at undue risk. This includes arrhythmia or tachyarrhythmia related to GD, such as atrial fibrillation or atrial flutter not sufficiently controlled with medications. * Graves' orbitopathy/Thyroid Eye Disease (GO/TED) requiring systemic therapy (eg, corticosteroids), orbital injections, orbital surgery, or orbital radiation, or expected immediate surgical intervention and/or planned corrective surgery/irradiation or medical therapy during the study.

Eignung in einfachen Aussagen

Die Kriterien dieses Eintrags wurden noch nicht in einzelne Aussagen aufgeschlüsselt. Der Registertext oben ist vollständig und ist die maßgebliche Fassung.

Studiendesign

Studiendesign
StudientypInterventionell
PhasePhase 3
ZuteilungRandomisiert
InterventionsmodellPARALLEL
Primäres ZielTREATMENT
VerblindungQUADRUPLE (4)
Teilnahme230 Teilnehmende gesucht

Sponsor und Mitwirkende

  • argenx Sponsor

Studienarme und Interventionen

  • Part A - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part A - placebo PH20 SC PFSPLACEBO_COMPARATOR

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part A double-blinded treatment period.

  • Part B - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part B - placebo PH20 SC PFSEXPERIMENTAL

    Participants will receive placebo PH20 SC Via Prefilled Syringe (PFS) during the part B treatment period.

  • Part C - efgartigimod PH20 SC PFSEXPERIMENTAL

    Participants will receive efgartigimod PH20 SC PFS in the part C open-label treatment period

Interventionen

  • Biologikum Efgartigimod PH20 SC

    Subcutaneous injection of Efgartigimod PH20 Via Prefilled Syringe (PFS)

  • Sonstige Placebo PH20 SC

    Subcutaneous injection of placebo PH20 via Prefilled Syringe (PFS)

Endpunkte

  1. Primärer Endpunkt

    Percentage of participants who are euthyroid (fT3, fT4, and TSH within normal ranges) off ATDs at week 24 in part A

    Free triiodothyronine: \[fT3\]; free thyroxine: \[fT4\]; ATDs: antithyroid drugs

    Zeitrahmen Up to 24 weeks (part A)

  2. Sekundärer Endpunkt

    Time to becoming euthyroid off ATDs in part A

    ATDs: antithyroid drugs

    Zeitrahmen Up to 24 weeks (part A)

  3. Sekundärer Endpunkt

    Percentage of participants who are euthyroid and receiving MMI ≤5 mg/day or CBZ ≤7.5 mg/day at week 24 in part A

    MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    Zeitrahmen Up to 24 weeks (part A)

  4. Sekundärer Endpunkt

    Percentage of participants with fT3 and fT4 levels below the ULN off ATDs at week 24 in part A

    ULN : upper limit of normal; ATDs: antithyroid drugs.

    Zeitrahmen Up to 24 weeks (part A)

  5. Sekundärer Endpunkt

    Percentage of participants who are euthyroid off ATDs and TRAb seronegative at week 24 in part A

    TRAb: anti-TSHR autoantibodies; ATDs: antithyroid drugs.

    Zeitrahmen Up to 24 weeks (part A)

  6. Sekundärer Endpunkt

    Time to becoming euthyroid off ATDs and TRAb seronegative

    ATDs: antithyroid drugs; TRAb: anti-TSHR autoantibodies.

    Zeitrahmen Up to 24 weeks (part A) + up to 135 weeks

  7. Sekundärer Endpunkt

    Time to becoming euthyroid and receiving an ATD dose of MMI ≤5 mg/day or CBZ ≤7.5 mg/day (part A)

    ATDs: antithyroid drugs; MMI: methimazole (also known as thiamazole); CBZ: carbimazole.

    Zeitrahmen Up to 24 weeks (Part A)

  8. Sekundärer Endpunkt

    Time to becoming euthyroid

    Zeitrahmen Up to 24 weeks (part A) + up to 135 weeks

  9. Sekundärer Endpunkt

    Time to having TSH within normal ranges among participants who have TSH lower than the LLN at baseline (part A)

    TSH: thyroid-stimulating hormone; LLN: lower limit of normal.

    Zeitrahmen Up to 24 weeks (part A)

  10. Sekundärer Endpunkt

    Percentage of participants who remain euthyroid without ATDs

    ATDs: antithyroid drug

    Zeitrahmen Up to 74 weeks (part B)

  11. Sekundärer Endpunkt

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS for 6, 12, and 18 months

    ATDs: antithyroid drug

    Zeitrahmen Up to 74 weeks (part B) + up to 135 weeks

  12. Sekundärer Endpunkt

    Percentage of participants who remain euthyroid without ATDs and without efgartigimod PH20 SC PFS

    ATDs: antithyroid drug

    Zeitrahmen Up to 72 weeks (part C)

  13. Sekundärer Endpunkt

    Incidence of AEs and SAEs

    AEs: adverse events ; SAEs: serious adverse events.

    Zeitrahmen Up to 135 weeks

  14. Sekundärer Endpunkt

    Change in ThyPRO-39 over time

    The Thyroid-Specific Patient-Reported Outcome Short Form (ThyPRO-39) 39 item version of the ThyPRO. Each item is related to a specific aspect of the participant's experience with their thyroid condition. Each item is scored on a 5-point Likert scale, and the scores are then transformed to a 0-to-100 scale. Higher scores indicate worse health status.

    Zeitrahmen Up to 135 weeks

  15. Sekundärer Endpunkt

    Change in PROMIS-PF10a over time

    The Patient-Reported Outcomes Measurement Information System Physical Function-10 item (PROMIS-PF10a) is a self-administered physical functioning assessment comprising 10 items that measure respondents' ability to perform common physical tasks. Scoring involves summing the numerical responses to each item; higher scores indicate better physical function.

    Zeitrahmen Up to 135 weeks

  16. Sekundärer Endpunkt

    Efgartigimod serum concentrations over time

    Zeitrahmen Up to 24 weeks (part A) + 72 weeks (part C)

  17. Sekundärer Endpunkt

    Percentage change from baseline in total IgG levels in serum over time

    IgG: immunoglobulin G

    Zeitrahmen Up to 98 weeks

  18. Sekundärer Endpunkt

    Percentage change from baseline in TRAb serum levels over time

    TRAb: anti-TSHR autoantibodies.

    Zeitrahmen Up to 135 weeks

  19. Sekundärer Endpunkt

    Incidence of ADA against efgartigimod in serum

    ADA: antidrug antibody(ies)

    Zeitrahmen Up to 24 weeks (part A) + up to 135 weeks

  20. Sekundärer Endpunkt

    Incidence of antibodies against rHuPH20 in plasma

    rHuPH20: recombinant human hyaluronidase PH20

    Zeitrahmen Up to 24 weeks (part A) + Up to 135 weeks

  21. Sekundärer Endpunkt

    Incidence of NAb against efgartigimod in serum and rHuPH20 in plasma

    NAb: neutralizing antibody(ies); rHuPH20: recombinant human hyaluronidase PH20.

    Zeitrahmen Up to 24 weeks (part A) + up to 135 weeks

Daten

Daten
Startdatum10. Juni 2026 (tatsächlich)
Primärer Abschluss1. Juni 2028 (geschätzt)
Abschluss1. Mai 2030 (geschätzt)
Erstveröffentlichung6. Mai 2026 (tatsächlich)
Zuletzt aktualisiert3. November 2026
Ergebnisse veröffentlichtIm Registereintrag nicht angegeben
Status zuletzt bestätigtSeptember 2026

Tatsächlich bedeutet, dass das Ereignis eingetreten ist. Geschätzt bedeutet, dass der Sponsor es erwartet. Die beiden bedeuten Unterschiedliches.

Standorte

35 Studienzentren rekrutieren

Georgia

Georgia
EinrichtungStadtBundesland oder RegionStatus
LLC American Hospital NetworkTbilisiRekrutiert
In Vitro Fertilization Center LLCTbilisiRekrutiert
LLC Todua ClinicTbilisiRekrutiert
New HospitalsTbilisiRekrutiert
LTD Israeli-Georgian Medical Research Clinic HealthycoreTbilisiRekrutiert

United Kingdom

United Kingdom
EinrichtungStadtBundesland oder RegionStatus
Queen Elizabeth Hospital (Gateshead Health NHS Foundation Trust)GatesheadTyne and WearRekrutiert

United States

United States
EinrichtungStadtBundesland oder RegionStatus
Albany Medical College Community EndocrinologyAlbanyNew YorkRekrutiert
University of MichiganAnn ArborMichiganRekrutiert
Asheville Clinical ResearchAshevilleNorth CarolinaRekrutiert
Profound Research LLC at Tri-City Primary CareCarlsbadCaliforniaRekrutiert
Research Institute of DallasDallasTexasRekrutiert
Metro Detroit Endocrinology CenterDearbornMichiganRekrutiert
Frontier Medical Center - Academy of Diabetes Thyroid and EndocrineEl PasoTexasRekrutiert
Profound ResearchFarmington HillsMichiganRekrutiert
Northeast Florida Endocrine & Diabetes Associates (NEFEDA) - Orange Park LocationFleming IslandFloridaRekrutiert
The Center for Diabetes and Endocrine CareFort LauderdaleFloridaRekrutiert
Juno ResearchHoustonTexasRekrutiert
Clinic of EndocrinologyHoustonTexasRekrutiert
Tekton Research IrvingIrvingTexasRekrutiert
University of Florida Jacksonville College of MedicineJacksonvilleFloridaRekrutiert
Truman Medical CenterKansas CityMissouriRekrutiert
Ilumina Medical Research LLCKissimmeeFloridaRekrutiert
Johnson County Clin-Trials, Inc.LenexaKansasRekrutiert
Biopharma Informatic, LLCMcAllenTexasRekrutiert
Tekton Research - McKinneyMcKinneyTexasRekrutiert
Southern Endocrinology Associates PAMesquiteTexasRekrutiert
Oceane 7 Medical & Research Center, IncMiamiFloridaRekrutiert
Endocrine Associates of West Village PCNew YorkNew YorkRekrutiert
Diabetes Associates Medical GroupOrangeCaliforniaRekrutiert
Havana Research Institute LLC.PasadenaCaliforniaRekrutiert
Pasadena Clinical TrialsPasadenaCaliforniaRekrutiert
Wake Internal Medicine ConsultantsRaleighNorth CarolinaRekrutiert
San Jose Clinical TrialsSan JoseCaliforniaRekrutiert
Consano Clinical ResearchShavano ParkTexasRekrutiert
Alliance for Multispecialty Research, LLCWichitaKansasRekrutiert

Studiendokumente

In diesem Registereintrag sind keine Dokumente verlinkt.

Änderungen im Zeitverlauf

  1. 3. November 2026

    Studienzentrum hinzugefügt

    3 sites added (35 total)

    3235

  2. 16. Oktober 2026

    Studienzentrum hinzugefügt

    6 sites added (32 total)

    2632

  3. 22. September 2026

    Studienzentrum hinzugefügt

    3 sites added (26 total)

    2326

  4. 17. September 2026

    Studienzentrum hinzugefügt

    1 site added (23 total)

    2223

  5. 12. August 2026

    Studienzentrum hinzugefügt

    4 sites added (22 total)

    1822